Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by Stylesson Aug 18, 2015 11:49am

66 Views

Post# 24027895

RE:RE:RE:RE:RE:RE:Lol

It's not luck. That's what you fail to understand / appreciate / acknowledge.

Company did dilutive M and A that disappointed the market
company reached steady state wrt to market share
eventually people will not give you a premium valuation for a one hit mature drug
wonder
Ongoing litigation issues
shitty pharma partners
chart just looked awful from a technical perspective

could have said a lot of money just picking up on the simple facts

Bullboard Posts

Global Tungsten Market and Supply Security